Replies to post #210686 on Biotech Values

[xavierprivas]

I used to own GLPG but I have not followed it closely after I sold it in
the 60s. I was disappointed at the low royalty rate for filgotinib in
RA and CF with Abbvie. I think they get a better deal in RA with GILD
after Abbvie dropped filgotinib in RA but I am not sure. FWIW

[Whalatane]

GLPG thx for the responses

Kiwi

[ghmm]

GLPG:

It would be nice to know more details of the baricitinib CRL to better gage the impact on future JAK's in RA. For what its worth my impression from the press release was Lilly was going to try to do some sort of appeal by the wording of their opinion.

I will defer to PGS and others with the science background to compare JAK's safety profile. It was interesting in their 4 week studies filgotinib seemed to have a positive effect on Lipids but not in the 12/24 week studies. One additional safety concern for those considering GLPG is FDA initially would not let them dose male subjects at 200mg because of a testicular tox issue found in preclinical testing (which has not been seen in male subjects).

I thought it interesting $INCY dropped about 2.75B in market cap with the CRL news. GLPG has a higher royalty (tiered starting at 20%) and significant milestones (was 1.35B at time of signing but that covers a multitude of indications). Their market cap was about 4.2B and 1B in cash (pre offering). So far I am impressed with Phase 2's GILD is initiating they aren't being cheap they are fairly larger Phase 2's (in addition to the Phase 3's for Crohn's and ulcerative colitis). And then their is their CF opportunity (mid-teens - 20%) I would be happy if they used the proceeds from their offering to buyout out their x-filgotinib partner :-). A couple of earlier assets two OA, 2 IPF programs, Atopic dermatitis)